Cephalon exercises option to acquire Ception
This article was originally published in Scrip
Executive Summary
Cephalon is to pay $250 million to acquire the private US firm Ception Therapeutics after its lead compound Cinquil (reslizumab) achieved positive Phase II data in a study in adults with eosinophilic asthma.